
Please try another search
International Stem Cell Corp (OTC:ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.
Second cohort enrolled in PD trial
In March 2018, the company announced it had completed dosing of the second cohort of four patients in its Phase I trial of ISC-hpNSC in PD, who are being treated with the 50m cell dose. As a reminder, patients on the study are being treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. Interim data from the first cohort, who were treated at the 30m cell dose, are encouraging. The company expects to start a Phase II PD trial later in 2018.
To read the entire report Please click on the pdf File Below:
While it isn't common knowledge, some tech stocks offer great dividend yields In fact, they far exceed the S&P 500's 1.3% yield Using insights from InvestingPro, let's delve...
U.S. 10-year Treasury yields have climbed to 16-year highs as investors digest the Federal Reserve's higher-for-longer rate mantra. As such, I used the InvestingPro stock screener...
Yesterday was a slam dunk day for the bears as whatever support, such as the retention of 4,325 in the S&P 500, was sliced apart. We are now looking at measured move targets for...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.